March 2024 in “Clinical, cosmetic and investigational dermatology” Severe alopecia areata greatly impacts quality of life, mental health, and daily activities.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
12 citations
,
March 2004 in “International Journal of Dermatology” Woman's hair loss diagnosis changed from CTE to AA; multiple biopsies important for accurate diagnosis.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.
January 2011 in “International Journal of Trichology” The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.
January 2026 in “Digital Repository (National Repository of Grey Literature)” Certain treatments, especially MZT1 and PRP2, effectively improve hair density and thickness in androgenetic alopecia.
1 citations
,
January 2021 in “Journal of Cutaneous and Aesthetic Surgery” Low-level light therapy can safely and effectively stimulate hair growth in people with androgenetic alopecia.